• <font id="bhr3f"><span id="bhr3f"><delect id="bhr3f"></delect></span></font>

    Stopping Cancer Before It Starts

    Antiva is developing novel topical therapies to treat pre-cancerous lesions caused by HPV. Our passionate, experienced team is dedicated to improving health outcomes and access to care worldwide. We aim to empower patients with safe, effective treatment options, address health care disparities in underserved communities, and save lives globally. Our non-surgical treatment approach offers a simple and convenient alternative to stop HPV and precancerous lesions before they become cancer.

    Antiva in the

    November 2, 2021

    Antiva Biosciences Closes $31 Million Series D Equity Financing Read more

    April 21, 2021

    Antiva Biosciences Appoints Clifford Samuel to Board of Directors Read more

    August 16, 2018

    A Women’s Health Startup Tried to Drum Up Interest for a Much-Needed Drug. Many Men Didn’t Get It Read article (pdf)